| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.BBMT.2006.05.015 |
| P698 | PubMed publication ID | 16920562 |
| P50 | author | Richard A. Larson | Q41899936 |
| Koen van Besien | Q43263315 | ||
| P2093 | author name string | Daniel A Pollyea | |
| Masha Kocherginsky | |||
| Olatoyosi Odenike | |||
| Wendy Stock | |||
| Todd Zimmerman | |||
| Andrew S Artz | |||
| Martine Extermann | |||
| Lucy Godley | |||
| Elizabeth Rich | |||
| Sonali Smith | |||
| Christopher Daugherty | |||
| Michael Thirman | |||
| P433 | issue | 9 | |
| P921 | main subject | comorbidity | Q1414874 |
| P304 | page(s) | 954-964 | |
| P577 | publication date | 2006-09-01 | |
| P1433 | published in | Biology of Blood and Marrow Transplantation | Q15754328 |
| P1476 | title | Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation | |
| P478 | volume | 12 |
| Q33829105 | A modified EBMT risk score and the hematopoietic cell transplantation-specific comorbidity index for pre-transplant risk assessment in adult acute lymphoblastic leukemia |
| Q52898922 | A modified EBMT risk score predicts the outcome of patients with acute myeloid leukemia receiving allogeneic stem cell transplants. |
| Q84626303 | A modified comorbidity index for hematopoietic cell transplantation |
| Q36402045 | A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation. |
| Q35766718 | Allogeneic hematopoietic cell transplantation in septuagenarians |
| Q33743786 | Assessment of the hematopoietic cell transplantation comorbidity index in non-Hodgkin lymphoma patients receiving reduced-intensity allogeneic hematopoietic stem cell transplantation |
| Q35591760 | Blood and marrow transplant clinical trials network state of the Science Symposium 2014 |
| Q80337198 | Chimerism does not predict for outcome after alemtuzumab based conditioning |
| Q59342684 | Clinical comorbidity predictive measures in ex vivo T-cell-depleted allogeneic hematopoietic stem cell transplantation |
| Q35664302 | Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score |
| Q37938531 | Current status of allogeneic transplantation for aggressive non-Hodgkin lymphoma |
| Q39044162 | Current treatment strategies in relapsed/refractory mantle cell lymphoma: where are we now? |
| Q36543682 | Defining vulnerability in allogeneic transplants is more complicated than the two numerical digits of age |
| Q35006910 | Early toxicity predicts long-term survival in high-grade glioma |
| Q47869630 | Frailty: the missing piece of the pre- hematopoietic cell transplantation assessment? |
| Q50058648 | Geriatric assessment and quality of life in older patients considered for allogeneic hematopoietic cell transplantation: a prospective risk factor and serial assessment analysis |
| Q33978945 | Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. |
| Q34583041 | Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences |
| Q46724769 | Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation |
| Q90459507 | Heterogeneous impact of cytomegalovirus reactivation on nonrelapse mortality in hematopoietic stem cell transplantation |
| Q48248668 | Impact of comorbidities constituting the hematopoietic cell transplant (HCT)-comorbidity index on the outcome of patients undergoing allogeneic HCT for acute myeloid leukemia |
| Q37087373 | Impact of comorbidity indexes on non-relapse mortality. |
| Q94600301 | Multidimensional geriatric assessment for elderly hematological patients (≥60 years) submitted to allogeneic stem cell transplantation. A French-Italian 10-year experience on 228 patients |
| Q37308127 | Non-myeloablative allogeneic hematopoietic stem cell transplantation |
| Q34514273 | Optimal screening for geriatric assessment in older allogeneic hematopoietic cell transplantation candidates |
| Q89485899 | Patient eligibility for hematopoietic stem cell transplantation: a review of patient-associated variables |
| Q38287009 | Patient selection for allogeneic hematopoietic cell transplantation (HCT): the evolution of HCT risk assessment |
| Q36447635 | Patient-reported physical functioning predicts the success of hematopoietic cell transplantation (BMT CTN 0902) |
| Q53209394 | Performance status, but not the hematopoietic cell transplantation comorbidity index (HCT-CI), predicts mortality at a Canadian transplant center. |
| Q45006970 | Pharmacokinetic targeting of i.v. BU with fludarabine as conditioning before hematopoietic cell transplant: the effect of first-dose area under the concentration time curve on transplant-related outcomes |
| Q96817610 | Pilot prospective study of Frailty and Functionality in routine clinical assessment in allogeneic hematopoietic cell transplantation |
| Q37157282 | Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation |
| Q83389146 | Prognostic factors in patients aged 50 years or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancy |
| Q57892716 | Prognostic value of comorbidity for auto-SCT eligibility and outcome in relapsed or refractory aggressive non-Hodgkin's lymphoma |
| Q35882830 | Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study |
| Q35845470 | Race/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization |
| Q38937601 | Recommended screening and preventive evaluation practices of adult candidates for hematopoietic stem cell transplantation |
| Q36137533 | Rehabilitation referrals and outcomes in the early period after hematopoietic cell transplantation |
| Q36569919 | Return to primary service among bone marrow transplant rehabilitation inpatients: an index for predicting outcomes |
| Q36920394 | Review of stem-cell transplantation for myelodysplastic syndromes in older patients in the context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome emanating from the Centers for Medicare and M |
| Q37419348 | Risk assessment before allogeneic hematopoietic cell transplantation for older adults with acute myeloid leukemia |
| Q37884884 | Stem cell transplantation for indolent lymphoma: a reappraisal |
| Q33870341 | Survival Impact of Early Post-Transplant Toxicities in Pediatric and Adolescent Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Malignant and Nonmalignant Diseases: Recognizing Risks and Optimizing Outcomes |
| Q36741749 | T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapse |
| Q38347135 | THE STATE OF CANCER REHABILITATION. |
| Q38230693 | The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma |
| Q33573495 | The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes |
| Q35061893 | Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes |
Search more.